Document is current
Any future updates will be listed below
-
Authors
Katakami, Naoto https://orcid.org/0000-0001-9020-8320
Mita, Tomoya
Masuda, Takafumi
Sato, Yasunori
Watada, Hirotaka
Shimomura, Iichiro
,
-
Clinical Trials BETA
Clinical trials referenced in this document:
umin000017607 at UMIN JapanDocuments that mention this clinical trial
The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus
https://doi.org/10.1007/s13300-021-01125-8
Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial
https://doi.org/10.1186/s12933-020-01206-1
Changes in serum levels of liver-related parameters, uric acid, and hemoglobin in patients with type 2 diabetes mellitus under treatment with tofogliflozin—a post-hoc analysis of the UTOPIA study
https://doi.org/10.1007/s13340-024-00693-x
Effect of tofogliflozin on obesity-related health problems in patients with type 2 diabetes and overweight or obesity—a post-hoc sub-analysis of the UTOPIA study
https://doi.org/10.1007/s13340-025-00845-7
-
Funding
Funding for this research was provided by:
Kowa Company
- License Information
-
More Information
Article History
Received: 31 March 2025
Accepted: 1 August 2025
First Online: 18 August 2025
Declarations
:
: NK received lecture fees from Abbott Japan Co., Ltd., Astellas Pharma Inc., Eli Lilly Japan K.K., Kowa Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Mitsubishi Tanabe Pharma Co., MSD K.K., Nippon Boehringer Ingelheim Co., Novo Nordisk Pharma, Ono Pharmaceutical Co., Sanofi-Aventis, Sanwa Kagaku Kenkyusho Co., Sumitomo Pharma Co., Taisho Toyama Pharmaceutical Co., and Teijin Pharma and research funds from Kowa Co. Ltd. TM has received lecture fees from Kissei Pharmaceutical Co. Ltd., Kowa Pharmaceutical Co., Ono Pharmaceutical Co. Ltd., Novo Nordisk Pharma Ltd., Sanofi-Aventis K.K., Daiichi Sankyo Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Mitsubishi Tanabe Pharma Corporation, MSD, and Teijin Pharma Company. TM has nothing to declare. YS has received lecture fees from Mochida Pharmaceutical Co., Ltd, Eisai Co., Ltd. and Eli Lilly and Company. HW has received research support from Sanwa Kagaku Kenkyusho Co., Ltd., Kowa Company, Ltd., Nippon Boehringer Ingelheim Co., Ltd., Sumitomo Pharma Co., Ltd., and SBI Pharma CO., Ltd., and has acted as a speaker for Novo Nordisk Pharma Ltd., Nippon Boehringer Ingelheim Co., Sumitomo Pharma Co., Ltd., Eli Lilly Japan K.K., Roche DC Japan, MSD K.K., Sanwa Kagaku Kenkyusho Co., Ltd., Daiichi Sankyo Ltd., Kyowa Kirin Co., Ltd., Bayer Yakuhin, Ltd., and Abbott Japan LLC. IS has received lecture fees from Abbott Japan Co., Ltd., Astellas Pharma Inc., AstraZeneca K.K., Bayer Yakuhin, Ltd., Chugai Pharmaceutical Co., Ltd., Covidien Japan Inc., Daiichi Sankyo Co., Eli Lilly Japan K.K, Fuji Yakuhin Co., Ltd., Johnson & Johnson K.K., Kowa Company, Ltd., KYORIN Pharmaceutical Co., Ltd., Kyowa Kirin Co. Ltd., Mitsubishi Tanabe Pharma Co., Mochida Pharmaceutical Co., MSD K.K., Nippon Boehringer Ingelheim Co., Novartis Pharma K.K., Novo Nordisk Pharma, Ono Pharmaceutical Co., Otsuka Pharmaceutical Co., Ltd., Sanofi K.K., Sanwa Kagaku Kenkyusho Co., Shionogi & Co., Ltd., Sumitomo Pharma Co., Taisho Pharmaceutical Co. Ltd., Takeda Pharma K.K., Teijin Pharma, Terumo Corporation; research funds from KOBAYASHI Pharmaceutical Co. Ltd., Kowa Co. Ltd., Rohto Pharmaceutical Co. Ltd., and scholarship donations from Daiichi Sankyo Co., Eli Lilly Japan K.K, Kowa Co. Ltd., Kyowa Kirin Co. Ltd., Mitsubishi Tanabe Pharma Co., Mochida Pharmaceutical Co., Sumitomo Pharma Co., Takeda Pharma K.K., and Teijin Pharma.
: The study was conducted in accordance with the Declaration of Helsinki, Ethical Guidelines for Medical and Health Research Involving Human Subjects, Clinical Trials Act, and other current legal regulations in Japan.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and/or with the Helsinki Declaration of 1964 and later versions. Informed consent or a substitute for it was obtained from all patients for being included in the study.
